Research map: Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Back to the article

Papers in this map

  1. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study · IRENE M. STRATTON · 2000 · 9133 citations · Cited by this paper
  2. Elevated serum galectin‐3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10‐year follow‐up study · 2026 · Related
  3. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  4. Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial · 2026 · Related
  5. Revised Equations for Estimated GFR From Serum Creatinine in Japan · Seiichi Matsuo · 2009 · 6537 citations · Cited by this paper
  6. Machine learning‐based prediction model for adverse pregnancy outcomes in women with gestational diabetes mellitus · 2026 · Related
  7. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study · Amanda Adler · 2000 · 2158 citations · Cited by this paper
  8. Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐ TZP study data · 2026 · Related
  9. Diabetic kidney disease · Merlin C. Thomas · 2015 · 1256 citations · Cited by this paper
  10. Response to: Methodological concerns on the predictive performance evaluation of anthropometric indices · 2026 · Related
  11. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data · Kunihiro Matsushita · 2015 · 923 citations · Cited by this paper
  12. Sudomotor dysfunction in people with type 1 diabetes with and without clinical peripheral neuropathy: A study from Pune, India · 2026 · Related
  13. Pathogenesis, prevention, and treatment of diabetic nephropathy · Mark Emmanuel Cooper · 1998 · 562 citations · Cited by this paper
  14. Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy · 2026 · Related
  15. Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy · Sho‐ichi Yamagishi · 2010 · 393 citations · Cited by this paper
  16. Improved prognosis prediction of all‐cause mortality and cardiovascular events by combined assessment of both ankle‐brachial index and brachial‐ankle pulse wave velocity in individuals with diabetes: The Kyushu prevention study for atherosclerosis, a prospective, multicenter survey · 2026 · Related
  17. Glycemic Control and Complications in Type 2 Diabetes Mellitus · MARK W. STOLAR · 2010 · 359 citations · Cited by this paper
  18. The miR ‐145‐5p/ NRF2 / SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy · 2026 · Related
  19. Oxidative stress in early diabetic nephropathy: fueling the fire · Dhruv K. Singh · 2010 · 356 citations · Cited by this paper
  20. USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6 ‐induced ferroptosis and angiogenesis inhibition · 2026 · Related
  21. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies · Josef Coresh · 2019 · 336 citations · Cited by this paper
  22. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) · Sadayoshi Ito · 2020 · 231 citations · Cited by this paper
  23. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes · Makoto Ohara · 2016 · 109 citations · Cited by this paper
  24. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial · Natalie Staplin · 2023 · 98 citations · Cited by this paper
  25. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 · Mandeep Singh Bajaj · 2025 · 91 citations · Cited by this paper
  26. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy · Joshua Jianxin Wang · 2008 · 85 citations · Cited by this paper
  27. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy · Susumu Ogawa · 2009 · 73 citations · Cited by this paper
  28. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes · Makoto Ohara · 2018 · 57 citations · Cited by this paper
  29. Receptor for advanced glycation endproducts and progressive kidney disease · Kei Fukami · 2014 · 48 citations · Cited by this paper
  30. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study · Sadayoshi Ito · 2021 · 36 citations · Cited by this paper
  31. RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice · Kensei Taguchi · 2018 · 33 citations · Cited by this paper
  32. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products · Takanori Matsui · 2015 · 25 citations · Cited by this paper
  33. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression · George L. Bakris · 2022 · 21 citations · Cited by this paper
  34. The mineralocorticoid receptor in diabetic kidney disease · Guanghong Jia · 2024 · 18 citations · Cited by this paper
  35. Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes · Tomoki Fujikawa · 2021 · 6 citations · Cited by this paper
  36. The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria · Rie Tatsugawa · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)